Yujun Zhao

Prof. Yujun Zhao

College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, Zhejiang, China
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Cancer Cell
Verified
Journal Article
Closed access
LBLongchuan Bai
Longchuan Bai
HZHaibin Zhou
Haibin Zhou
RXRenqi Xu
Renqi Xu
Yujun ZhaoYujun Zhao
Yujun Zhao
KCKrishnapriya Chinnaswamy
Krishnapriya Chinnaswamy
SWShaomeng Wang
Shaomeng Wang

14 November 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
Yujun ZhaoYujun Zhao
Yujun Zhao
AAAngelo Aguilar
Angelo Aguilar
DBDenzil Bernard
Denzil Bernard
SWShaomeng Wang
Shaomeng Wang
Design of small-molecule inhibitors (MDM2 inhibitors) to block the MDM2–p53 protein–protein interaction has been pursued as a new cancer therapeutic strategy. In recent years, potent, selective, and efficacious MDM2 inhibitors have been successfully obtained and seven such compounds have been advanced into early phase clinical trials for the treatment of human cancers. Here, we review the design, synthesis, properties, preclinical, and clinical studies of these clinical-stage MDM2 inhibitors.

24 March 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
BZBing Zhou
Bing Zhou
JHJiantao Hu
Jiantao Hu
FXFuming Xu
Fuming Xu
ZCZhuo Chen
Zhuo Chen
LBLongchuan Bai
Longchuan Bai
SWShaomeng Wang
Shaomeng Wang
The bromodomain and extra-terminal (BET) family proteins, consisting of BRD2, BRD3, BRD4, and testis-specific BRDT members, are epigenetic “readers” and play a key role in the regulation of gene transcription. BET proteins are considered to be attractive therapeutic targets for cancer and other human diseases. Recently, heterobifunctional small-molecule BET degraders have been designed based upon the proteolysis targeting chimera (PROTAC) concept to induce BET protein degradation. Herein, we present our design, synthesis, and evaluation of a new class of PROTAC BET degraders. One of the most promising compounds, 23, effectively degrades BRD4 protein at concentrations as low as 30 pM in the RS4;11 leukemia cell line, achieves an IC50 value of 51 pM in inhibition of RS4;11 cell growth and induces rapid tumor regression in vivo against RS4;11 xenograft tumors. These data establish that compound 23 (BETd-260/ZBC260) is a highly potent and efficacious BET degrader.

14 October 2014 in Cancer Research
Verified
Journal Article
Closed access
PDF file
SWShaomeng Wang
Shaomeng Wang
WSWei Sun
Wei Sun
Yujun ZhaoYujun Zhao
Yujun Zhao
DMDonna McEachern
Donna McEachern
IMIsabelle Meaux
Isabelle Meaux
LDLaurent Debussche
Laurent Debussche
Blocking the oncoprotein murine double minute 2 (MDM2)–p53 protein–protein interaction has long been considered to offer a broad cancer therapeutic strategy, despite the potential risks of selecting tumors harboring p53 mutations that escape MDM2 control. In this study, we report a novel small-molecule inhibitor of the MDM2–p53 interaction, SAR405838 (MI-77301), that has been advanced into phase I clinical trials. SAR405838 binds to MDM2 with Ki = 0.88 nmol/L and has high specificity over other proteins. A cocrystal structure of the SAR405838:MDM2 complex shows that, in addition to mimicking three key p53 amino acid residues, the inhibitor captures additional interactions not observed in the p53–MDM2 complex and induces refolding of the short, unstructured MDM2 N-terminal region to achieve its high affinity. SAR405838 effectively activates wild-type p53 in vitro and in xenograft tumor tissue of leukemia and solid tumors, leading to p53-dependent cell-cycle arrest and/or apoptosis. At well-tolerated dose schedules, SAR405838 achieves either durable tumor regression or complete tumor growth inhibition in mouse xenograft models of SJSA-1 osteosarcoma, RS4;11 acute leukemia, LNCaP prostate cancer, and HCT-116 colon cancer. Remarkably, a single oral dose of SAR405838 is sufficient to achieve complete tumor regression in the SJSA-1 model. Mechanistically, robust transcriptional upregulation of PUMA induced by SAR405838 results in strong apoptosis in tumor tissue, leading to complete tumor regression. Our findings provide a preclinical basis upon which to evaluate SAR405838 as a therapeutic agent in patients whose tumors retain wild-type p53. Cancer Res; 74(20); 5855–65. ©2014 AACR.

20 June 2013 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Yujun ZhaoYujun Zhao
Yujun Zhao
SYShanghai Yu
Shanghai Yu
WSWei Sun
Wei Sun
LLLiu Liu
Liu Liu
JLJianfeng Lu
Jianfeng Lu
SWShaomeng Wang
Shaomeng Wang

7 March 2017 in Cold Spring Harbor Perspectives in Medicine
Verified
Journal Article
Open access
PDF file
SWShaomeng Wang
Shaomeng Wang
Yujun ZhaoYujun Zhao
Yujun Zhao
AAAngelo Aguilar
Angelo Aguilar
DBDenzil Bernard
Denzil Bernard
CYChao-Yie Yang
Chao-Yie Yang
MDM2 is a primary cellular inhibitor of p53. It inhibits p53 function by multiple mechanisms, each of which, however, is mediated by their direct interaction. It has been proposed that small-molecule inhibitors designed to block the MDM2–p53 interaction may be effective in the treatment of human cancer retaining wild-type p53 by reactivating the p53 tumor suppressor function. Through nearly two decades of intense efforts, a number of structurally distinct, highly potent, nonpeptide, small-molecule inhibitors of the MDM2–p53 interaction (MDM2 inhibitors) have been successfully designed and developed, and at least seven such compounds have now been advanced into human clinical trials as new anticancer drugs. This review offers a perspective on the design and development of MDM2 small-molecule inhibitors and discusses early clinical data for some of the MDM2 small-molecule inhibitors and future challenges for the successful clinical development of MDM2 inhibitors for cancer treatment.